Acesso livre
Acesso livre

Oncologia

Estudo randomizado de fase 2 | Nivolumabe adjuvante com ipilimumabe ou nivolumabe isolado vs. placebo em pacientes com melanoma estágio IV ressecado sem nenhuma evidência de doença.

13 Set, 2022 | 11:43h

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial – The Lancet

 

Estudo randomizado | Sobrevida global com olaparibe de manutenção em um seguimento de 7 anos de pacientes com câncer de ovário avançado recém-diagnosticado e mutação no BRCA.

13 Set, 2022 | 11:40h

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial – Journal of Clinical Oncology

Comentário: Olaparib Maintenance Provides Sustained OS Benefit in Newly Diagnosed, BRCA-Mutated, Advanced Ovarian Cancer – OncLive

 

Estudo randomizado | Ripretinibe vs. sunitinibe em pacientes com tumor estromal gastrintestinal avançado após tratamento com imatinibe.

12 Set, 2022 | 11:08h

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial – Journal of Clinical Oncology

Editorial: Ripretinib and the Failure to Advance GI Stromal Tumor Therapy in the Age of Precision Medicine – Journal of Clinical Oncology

 

Comentário no Twitter

 

Estudo de coorte | Procedimentos de preservação da fertilidade parecem ser seguros no momento do diagnóstico do câncer de mama.

8 Set, 2022 | 14:14h

Relapse Rates and Disease-Specific Mortality Following Procedures for Fertility Preservation at Time of Breast Cancer Diagnosis – JAMA Oncology

Comunicado de imprensa: Fertility preservation measures do not appear to increase the risk of breast cancer recurrence – Karolinska Institutet

Comentário: Fertility Preservation Measures Do Not Appear to Increase the Risk of Breast Cancer Recurrence – The ASCO Post

 

Estudo randomizado de não inferioridade | Regime quimioterápico de indução de docetaxel com cisplatina vs. docetaxel, cisplatina e fluorouracil seguidos de quimioterapia no carcinoma nasofaríngeo avançado locorregional.

8 Set, 2022 | 13:50h

Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial – eClinicalMedicine

 

Estudo randomizado | Segmentectomia anatômica vs. lobectomia padrão para câncer de pulmão de não pequenas células de até 2 cm.

8 Set, 2022 | 13:46h

Survival outcomes in a prospective randomized multicenter Phase III trial comparing patients undergoing anatomical segmentectomy versus standard lobectomy for non-small cell lung cancer up to 2 cm – Lung Cancer

Conteúdos relacionados:

A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation.

Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial – The Lancet (link para o resumo – $ para o texto completo)

A Meta-Analysis Comparing Lobectomy versus Segmentectomy in Stage I Non-Small Cell Lung Cancer – The Korean Journal of Thoracic and Cardiovascular Surgery

 

Estudo de braço único fase 2 | Galunisertibe com quimioterapia neoadjuvante em pacientes com câncer retal localmente avançado.

8 Set, 2022 | 13:42h

Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial – The Lancet Oncology (link para o resumo – $ para o texto completo)

Comentários:

Addition of Galunisertib to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer – The ASCO Post

Improved Complete Response Rate Observed With Galunisertib Plus Neoadjuvant CRT in Advanced Rectal Cancer – Cancer Network

 

Revisão | Complicações cardiovasculares dos imunoterápicos para câncer.

8 Set, 2022 | 13:40h

Cardiovascular complications of immune checkpoint inhibitors for cancer – European Heart Journal

Conteúdos relacionados:

Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute—Cancer Therapy Evaluation Program – Journal of Clinical Oncology

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment – Journal of the American Heart Association

Cardiotoxicity of immune checkpoint inhibitors – ESMO Open

Cardiotoxicity from immune checkpoint inhibitors – IJC Heart & Vasculature

Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology – Journal of the Formosan Medical Association

Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock – JACC: CardioOncology

 

Comentário no Twitter

 

Opinião | Pessoas com câncer terminal precisam saber que estão morrendo. Médicos não deveriam reter essa informação.

6 Set, 2022 | 13:10h

People with terminal cancer need to know they are dying. Doctors shouldn’t withhold that information – STAT

Estudo relacionado: Association of Prognostic Understanding With Health Care Use Among Older Adults With Advanced Cancer: A Secondary Analysis of a Cluster Randomized Clinical Trial – JAMA Network Open

 

Seguimento de 5 anos de estudo randomizado | FOLFIRINOX vs. gencitabina como terapia adjuvante no câncer pancreático.

6 Set, 2022 | 13:00h

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial – JAMA Oncology (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.